Subscribe Us

header ads

Recents

header ads

Infectious Disease Diagnostics Market Size, Growth, Demands Outlook and Forecasts to 2032

According to the research report, the global infectious disease diagnostics market size is expected to touch USD 56.62 Billion by 2032, from USD 28.65 Billion in 2022, growing with a significant CAGR of 7.05% from 2023 to 2032.

Infectious Disease Diagnostics Market Size 2023 To 2032

Key Takeaways:

  • North America region is predicted to capture the largest market share between 2023 and 2032.
  • By Product, the assays & reagents segment generated more than 51% of revenue share in 2022.
  • By Technology, the immunodiagnostics segment is estimated to record the highest market share from 2023 to 2032.

The infectious disease diagnostics report offers a comprehensive study of the current state expected at the major drivers, market strategies, and key vendors’ growth. The report presents energetic visions to conclude and study the market size, market hopes, and competitive surroundings. The research also focuses on the important achievements of the market, research & development, and regional growth of the leading competitors operating in the market. The current trends of the global infectious disease diagnostics in conjunction with the geographical landscape of this vertical have also been included in this report.

The report offers intricate dynamics about different aspects of the global infectious disease diagnostics market, which aids companies operating in the market in making strategic development decisions. The study also elaborates on significant changes that are highly anticipated to configure growth of the global infectious disease diagnostics during the forecast period. It also includes a key indicator assessment that highlights growth prospects of this market and estimates statistics related to growth of the market in terms of value (US$ Mn) and volume (tons).

Sample Link @ https://www.precedenceresearch.com/sample/3100

This study covers a detailed segmentation of the global infectious disease diagnostics market, along with key information and a competition outlook. The report mentions company profiles of players that are currently dominating the global infectious disease diagnostics market, wherein various developments, expansions, and winning strategies practiced and implemented by leading players have been presented in detail.

Key Players

  • Abbott Laboratories
  • Becton Dickinson and Company
  • bioMerieus SA
  • Bio-Rad Laboratories
  • Danaher Corporation
  • F Hoffman-La Roche
  • Hologic Inc.
  • Luminex Corporation
  • Qiagen Inc.
  • Thermo Fisher Scientific Inc.

Market Segmentation

By Product

  • Assays & Reagents
  • Instruments
  • Software

By Disease Type

  • Hepatitis
  • Human Immunodeficiency Virus
  • Influenza
  • Others

By Technology

  • Immunodiagnostics
  • Clinical Microbiology
  • Polymerase Chain Reaction
  • Next-generation Sequencing
  • Others

By Geography

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

Research Methodology

The research methodology adopted by analysts for compiling the global infectious disease diagnostics report is based on detailed primary as well as secondary research. With the help of in-depth insights of the market-affiliated information that is obtained and legitimated by market-admissible resources, analysts have offered riveting observations and authentic forecasts for the global market.

During the primary research phase, analysts interviewed market stakeholders, investors, brand managers, vice presidents, and sales and marketing managers. Based on data obtained through interviews of genuine resources, analysts have emphasized the changing scenario of the global market.

For secondary research, analysts scrutinized numerous annual report publications, white papers, market association publications, and company websites to obtain the necessary understanding of the global infectious disease diagnostics market.

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Infectious Disease Diagnostics Market 

5.1. COVID-19 Landscape: Infectious Disease Diagnostics Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Infectious Disease Diagnostics Market, By Product

8.1. Infectious Disease Diagnostics Market, by Product, 2023-2032

8.1.1 Assays & Reagents

8.1.1.1. Market Revenue and Forecast (2020-2032)

8.1.2. Instruments

8.1.2.1. Market Revenue and Forecast (2020-2032)

8.1.3. Software

8.1.3.1. Market Revenue and Forecast (2020-2032)

Chapter 9. Global Infectious Disease Diagnostics Market, By Disease Type

9.1. Infectious Disease Diagnostics Market, by Disease Type, 2023-2032

9.1.1. Hepatitis

9.1.1.1. Market Revenue and Forecast (2020-2032)

9.1.2. Human Immunodeficiency Virus

9.1.2.1. Market Revenue and Forecast (2020-2032)

9.1.3. Influenza

9.1.3.1. Market Revenue and Forecast (2020-2032)

9.1.4. Others

9.1.4.1. Market Revenue and Forecast (2020-2032)

Chapter 10. Global Infectious Disease Diagnostics Market, By Technology 

10.1. Infectious Disease Diagnostics Market, by Technology, 2023-2032

10.1.1. Immunodiagnostics

10.1.1.1. Market Revenue and Forecast (2020-2032)

10.1.2. Clinical Microbiology

10.1.2.1. Market Revenue and Forecast (2020-2032)

10.1.3. Polymerase Chain Reaction

10.1.3.1. Market Revenue and Forecast (2020-2032)

10.1.4. Next-generation Sequencing

10.1.4.1. Market Revenue and Forecast (2020-2032)

10.1.5. Others

10.1.5.1. Market Revenue and Forecast (2020-2032)

Chapter 11. Global Infectious Disease Diagnostics Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Product (2020-2032)

11.1.2. Market Revenue and Forecast, by Disease Type (2020-2032)

11.1.3. Market Revenue and Forecast, by Technology (2020-2032)

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Product (2020-2032)

11.1.4.2. Market Revenue and Forecast, by Disease Type (2020-2032)

11.1.4.3. Market Revenue and Forecast, by Technology (2020-2032)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Product (2020-2032)

11.1.5.2. Market Revenue and Forecast, by Disease Type (2020-2032)

11.1.5.3. Market Revenue and Forecast, by Technology (2020-2032)

11.2. Europe

11.2.1. Market Revenue and Forecast, by Product (2020-2032)

11.2.2. Market Revenue and Forecast, by Disease Type (2020-2032)

11.2.3. Market Revenue and Forecast, by Technology (2020-2032)

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Product (2020-2032)

11.2.4.2. Market Revenue and Forecast, by Disease Type (2020-2032)

11.2.4.3. Market Revenue and Forecast, by Technology (2020-2032)

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Product (2020-2032)

11.2.5.2. Market Revenue and Forecast, by Disease Type (2020-2032)

11.2.5.3. Market Revenue and Forecast, by Technology (2020-2032)

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Product (2020-2032)

11.2.6.2. Market Revenue and Forecast, by Disease Type (2020-2032)

11.2.6.3. Market Revenue and Forecast, by Technology (2020-2032)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Product (2020-2032)

11.2.7.2. Market Revenue and Forecast, by Disease Type (2020-2032)

11.2.7.3. Market Revenue and Forecast, by Technology (2020-2032)

11.3. APAC

11.3.1. Market Revenue and Forecast, by Product (2020-2032)

11.3.2. Market Revenue and Forecast, by Disease Type (2020-2032)

11.3.3. Market Revenue and Forecast, by Technology (2020-2032)

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Product (2020-2032)

11.3.4.2. Market Revenue and Forecast, by Disease Type (2020-2032)

11.3.4.3. Market Revenue and Forecast, by Technology (2020-2032)

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Product (2020-2032)

11.3.5.2. Market Revenue and Forecast, by Disease Type (2020-2032)

11.3.5.3. Market Revenue and Forecast, by Technology (2020-2032)

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Product (2020-2032)

11.3.6.2. Market Revenue and Forecast, by Disease Type (2020-2032)

11.3.6.3. Market Revenue and Forecast, by Technology (2020-2032)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Product (2020-2032)

11.3.7.2. Market Revenue and Forecast, by Disease Type (2020-2032)

11.3.7.3. Market Revenue and Forecast, by Technology (2020-2032)

11.4. MEA

11.4.1. Market Revenue and Forecast, by Product (2020-2032)

11.4.2. Market Revenue and Forecast, by Disease Type (2020-2032)

11.4.3. Market Revenue and Forecast, by Technology (2020-2032)

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Product (2020-2032)

11.4.4.2. Market Revenue and Forecast, by Disease Type (2020-2032)

11.4.4.3. Market Revenue and Forecast, by Technology (2020-2032)

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Product (2020-2032)

11.4.5.2. Market Revenue and Forecast, by Disease Type (2020-2032)

11.4.5.3. Market Revenue and Forecast, by Technology (2020-2032)

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Product (2020-2032)

11.4.6.2. Market Revenue and Forecast, by Disease Type (2020-2032)

11.4.6.3. Market Revenue and Forecast, by Technology (2020-2032)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Product (2020-2032)

11.4.7.2. Market Revenue and Forecast, by Disease Type (2020-2032)

11.4.7.3. Market Revenue and Forecast, by Technology (2020-2032)

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Product (2020-2032)

11.5.2. Market Revenue and Forecast, by Disease Type (2020-2032)

11.5.3. Market Revenue and Forecast, by Technology (2020-2032)

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Product (2020-2032)

11.5.4.2. Market Revenue and Forecast, by Disease Type (2020-2032)

11.5.4.3. Market Revenue and Forecast, by Technology (2020-2032)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Product (2020-2032)

11.5.5.2. Market Revenue and Forecast, by Disease Type (2020-2032)

11.5.5.3. Market Revenue and Forecast, by Technology (2020-2032)

Chapter 12. Company Profiles

12.1. Abbott Laboratories

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. Becton Dickinson and Company

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. bioMerieus SA

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. Bio-Rad Laboratories

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Danaher Corporation

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. F Hoffman-La Roche

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. Hologic Inc.

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Luminex Corporation

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Qiagen Inc.

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. Thermo Fisher Scientific Inc.

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms

Contact Us:

Precedence Research

Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada

Call: +1 774 402 6168

Email: sales@precedenceresearch.com

Website: https://www.precedenceresearch.com

 Blog: https://www.pharma-geek.com

Post a Comment

0 Comments